Effect of somatostatin on fasting and glucose-stimulated gastric inhibitory polypeptide release in man.
The effect of intravenous somatostatin infusion on circulating gastric inhibitory polypeptide (GIP), insulin, glucagon and on blood glucose was investigated in 7 healthy volunteers in the fasting state and during the oral ingestion of 75 g glucose. Somatostatin (1.1 microgram/kg/h) infused 30 min before and continued 60 min after the ingestion of glucose did not affect fasting levels of any of the above parameters while it significantly suppressed the GIP and insulin response to glucose. The same somatostatin dose infused 30 min after the ingestion of glucose decreased significantly the raised levels of GIP and insulin and further increased blood glucose levels. It is concluded that somatostatin inhibits GIP release mainly at the level of the GIP-producing cells.
D000328:Adult; D005215:Fasting; D005746:Gastric Emptying; D005749:Gastric Inhibitory Polypeptide / Q000378:metabolism*; D005768:Gastrointestinal Hormones / Q000378:metabolism*; D005947:Glucose / Q000378:metabolism / Q000494:pharmacology*; D006801:Humans; D007328:Insulin / Q000378:metabolism; D000078790:Insulin Secretion; D007408:Intestinal Absorption; D008297:Male; D013004:Somatostatin / Q000494:pharmacology*
D005768:Gastrointestinal Hormones; D007328:Insulin; D013004:Somatostatin; D005749:Gastric Inhibitory Polypeptide; D005947:Glucose